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A B S T R A C T
Survivors of childhood cancer have a significantly higher late morbidity and mortality from cardiovascular diseases.
The aim of this study was to determine whether anthracyclines used in childhood could increase arterial stiffness, a
well-known independent predictor of cardiovascular diseases. The study included 53 children and adolescents aged
6–20 years having completed anthracycline treatment for a malignant disease according to various protocols at least a
year before. The patients were free from clinical or laboratory signs of the underlying disease or cardiac disease. Control
group consisted of 45 age- and sex-matched healthy children. Arterial stiffness was determined by measuring aortic
pulse wave velocity (PWVao) using oscillometric method (Arteriograph TensioMed device). PWVao value was signifi-
cantly increased (6.24±1.34 m/s vs. 5.42±0.69 m/s; p<0.001) in patients having received anthracyclines as compared to
control group. Increased arterial stiffness was present irrespective of the following parameters: age, sex, body mass in-
dex, systolic and diastolic blood pressure, mean arterial pressure and heart rate. It is possible that the effect of anthra-
cycline on increased cardiovascular morbidity and mortality in long-term childhood cancer survivors is associated not
only with cardiotoxicity, but also with increased arterial stiffness.
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Introduction
Anthracycline cardiotoxicity is one of the most seri-
ous complications of cancer therapy and could manifest
as cardiomyopathy, pericarditis and congestive heart fai-
lure1–3. Today, more than 75 percent of children treated
for childhood cancer can be cured4. For long-term survi-
vors, the possible late effects of treatment are a major
concern. Cardiac complications may appear long after
the end of anthracyclines treatment and are the leading
cause of morbidity and mortality in long-term survivors
of childhood cancer5. Mortality related to cardiac causes
in long-term survivors is tenfold that in control group6.
The mechanism of anthracycline cardiotoxicity is not en-
tirely clear, but oxidative stress plays an important role
in myocardial and vascular damage in patients treated
with anthracyclines7.
Increased stiffness of central arteries has been shown
to have an independent predictive value for cardiovascu-
lar events in adult population8. Since changes in blood
vessels occur much earlier than clinically developed disea-
se can be observed, arterial stiffness is a significant mar-
ker in the development of future cardiovascular changes.
Arterial stiffness increases normally during lifetime,
but could be further enhanced by atherosclerotic process
and diseases like hypertension, diabetes, dyslipidemia9,
and it is a marker of vascular disease. Arterial stiffness in
childhood is influenced by classic risk factors for cardio-
vascular disease (obesity, metabolic syndrome, familial
hypercholesterolemia, diabetes, physical inactivity)10–11
and additionally by prenatal growth retardation, vascu-
litis, vasculopathy, and congenital heart disease12. There
are several different methods to determine arterial stiff-
ness, but to determine the stiffness of central arteries,
measurement of aortic pulse wave velocity (PWVao) is
the one most commonly used13. PWVao is the speed at
which the forward pressure or flow wave is transmitted
from aorta through the arterial tree. Age, height, and
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mean arterial pressure (MAP) were found to be major de-
terminants of PWVao14.
Little is known about the possible impact of an-
thracycline to increased arterial stiffness as a potential
risk factor for later cardiovascular diseases15.
The aim of our study was to determine whether the
children having completed anthracycline treatment for a
malignant disease a year or more before, have an in-
creased central arterial stiffness measured by PWVao as
compared to age- and sex-matched healthy children. The
occlusive oscillometric method using Arteriograph is a
new, easy-to-use and time-effective method for assessing
arterial stiffness.
Patients and Methods
The study design was a case-control trial including 53
children and adolescents aged 6 to 20 years (34 (64.2%)
male and 19 (35.8%) female) having received an anthra-
cyclines (doxorubicin, epirubicin, daunorubicin) for the
treatment of malignant disease more than a year before
(cases), and 45 age- and sex-matched healthy controls.
Study patients were free from clinical and laboratory
signs of the underlying disease or cardiac disease. An-
thracycline chemotherapy was applied according to dif-
ferent chemotherapy protocols. Participants receiving
cancer treatment were diagnosed with osteosarcoma and
Ewing sarcoma (n=17), Hodgkin and non-Hodgkin lym-
phoma (n=9), Wilms tumor (n=4), neuroblastoma (n=4),
synovial sarcoma (n=3), rhabdomyosarcoma (n=3) and
other tumors (n=13).
Doxorubicin, epirubicin and daunorubicin were ad-
ministered as part of various chemotherapy protocols in
a total dose of 75–375 mg/m2 (212±93 mg/m2).
Cyclophosphamide, another possibly cardiotoxic
drug16, was administered in a dose of 7–42 mg/kg /day
(18.54±14,74), total dose of 0.70–7.20 g/m2 (4.37±3.00
g/m2). Additional chemotherapeutics included in differ-
ent protocols were antimetabolite methotrexate, alkaloid
vincristine, and the alkylating agent cisplatin. None of
the study patients received radiotherapy in the media-
stinal and abdominal area.
Exclusion criteria were patients with arrhythmia,
known renal, endocrine, cardiovascular or other chronic
disease, and course of corticosteroids or antihypertensive
therapy. Median time elapsed from the last chemother-
apy dose was 2 (range 1–16) years.
Control subjects were 45 healthy children and adoles-
cents aged 6 to 20 years (25 (55.6%) male and 20 (44.4%)
female), referred to cardiologist because of innocent heart
murmur and healthy volunteers. Sample size was com-
puted by power analysis for Mann-Whitney U test: mini-
mum total 94 subjects would make around 47 subjects
per group, with the parameter level of significance a=0.05,
estimated effect size d=0.6, power 0.80 (G*Power for
Windows 3.1.2; available from: http://www.psycho.uni-
-duesseldorf.de/aap/projects/gpower/).
All relevant information including both personal and
family history regarding the symptoms and signs associ-
ated with cardiovascular abnormalities were collected
using a questionnaire administered to study subjects and
their parents.
Children and adolescents underwent physical exami-
nation with special attention paid to symptoms and signs
associated with cardiovascular abnormalities. Anthro-
pometric measurements (body height and weight, waist
and hip circumference) were performed according to
standard procedures: waist circumference (cm) was mea-
sured in midline between the edge of lower rib cage and
iliac crest; hip circumference (cm) was measured at the
point of maximal width. Body mass index (BMI) was cal-
culated according to the equation: body weight (kg)/body
height2 (m2). Distance between the jugulum and sym-
physis (J-Sy) (cm) was measured from the upper edge of
manubrium sterni to the upper edge of symphysis, en-
suring that we measured the shortest distance between
these two points. The measurements were performed
twice and the mean values were used.
Blood pressure (BP; mm Hg) was measured in supine
position after 10-minute rest, with appropriate cuff, us-
ing the oscillometric device Philips Patient Monitor M
3926A. Each measurement was performed twice and the
mean value was used in further calculations.
Standard 12-chanel ECG was performed with Agilent
Pagewriter 100.
Echocardiography
Echocardiography was performed on HP SONOS 4500
machine with 4 MHz transducer. Complete examination
included two-dimensional echocardiography (2D), mo-
tion mode echocardiography (M-mode) and Doppler tech-
nique. The left ventricular (LV; cm) internal dimension,
interventricular septal thickness (IVS; cm) and LV poste-
rior wall thickness (LVPW; cm) were measured during di-
astole and systole according to the methods established
by the American Society of Echocardiography17. Mea-
surements for each parameter were performed twice and
the mean value was used in further calculations. Frac-
tional shortening (FS; %), left ventricle mass (LVM; g)
and left ventricle mass index (LVMI; g/m2.7) were calcu-
lated according to the previously published and standard
techniques18.
Arteriograph
The occlusive oscillometric method for measuring
PWVao by Arteriograph (TensioMed Ltd., Budapest, Hun-
gary; Software Arteriograph for Windows 2000) is based
on plethysmography recording of pulse wave oscillations
detected on the upper-arm cuff by a special high fidelity
sensor.
Pulse wave velocity (PWV)
The technique is based on the fact that during systole,
the blood volume ejected into the aorta generates a pulse
wave, so-called 'early systolic peak' (P1). As this pulse
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wave runs down, it reflects from the bifurcation of the
aorta, creating a second wave, so-called 'late systolic
peak' (P2). Return time (RT) is calculated as the differ-
ence in milliseconds between the first and the reflected
systolic wave. Aortic pulse wave velocity (PWVao) is cal-
culated from the return time and the distance traveled
by the pulse wave from the jugulum (sternal notch) to
the pubic symphysis, which is closest to the real length of
the aorta. This distance was measured on the body sur-






Standard deviation (SDPWVao) (m/s) indicates the qual-
ity of measurement, i.e. dispersion of PWVao values of
particular cardiac cycles. SDPWVao is calculated for PWVao
of each individual pulse wave. A mean of SDPWVao>1.1
m/s indicates unsatisfactory measurement and it should be
repeated. In the present study, it was less than 0.5 (m/s).
Besides PWVao, augmentation index (AIx), central
aortic systolic pressure (SBPao) aortic pulse pressure
(PPao) (mm Hg), mean arterial pressure (MAP) (mmHg)
and peripheral blood pressure (BP) are also determined
by use of Arteriograph.
Augmentation index (AIx) is a complex parameter
that provides information on systemic arterial stiffness
because it depends on peripheral resistance and pulse
wave velocity. There is strong correlation between aug-
mentation index of brachial artery (AIx br) and of aorta
(AIxao) (r=0.94; P<0.001)19. Augmentation index (AIx)
is on a decrease in children until age 15, then it rises. It




2 1− ´ 100 (%)
(P1, early systolic peak; P2, late systolic peak; PP, pulse
pressure)
Central systolic blood pressure (SBPao) (mmHg) could
be automatically calculated by direct analysis, without
the use of transfer function19, on the basis of peripheral
(brachial) pressure (BP) and brachial augmentation in-
dex (AIxbr), which correlates strongly with central aug-
mentation index (AIxao) (r=0.94; P<0.001).
Aortic pulse pressure (PPao) (mmHg)
PPao (mmHg) = SBPao–DBPao;
(SBPao, aortic systolic blood pressure; DBPao, aortic dia-
stolic blood pressure)






(SAP, brachial systolic pressure; DAP, brachial diastolic
pressure)
In recent years, three studies have been published
that compared the known noninvasive methods to deter-
mine arterial stiffness parameters: piezoelectronic me-
thod (Complior), applanation tonometry (SphygmoCor)
and oscillometric method (Arteriograph)20–22. Carotid-
-femoral PWV, a method used by SphygmoCor, is con-
sidered a 'gold standard'. There was no significant differ-
ence among the three methods in time measurements
(transit time = RT/2), whereas PWV differed due to the
mode of distance (pathway) measurement20. There was
significant correlation of PWV values obtained by Ar-
teriograph and SphygmoCor (r=0.67; p<0.001), and
Complior (r=0.69; p<0.001).
High correlation was found between AIx determined
by Arteriograph and SphygmoCor (r=0.92; p<0.001)21.
The PWV and AIx values recorded by Arteriograph cor-
related well with those obtained by use of Complior (r=
0.60; p<0.001) and SphygmoCor (r=0.89; p<0.001)22.
The advantage of occlusive oscillometric method by Ar-
teriograph over other methods is its simple use.
The latest study by Horvath et al.19 including 93 pa-
tients showed excellent correlation of PWVao values de-
termined by Arteriograph and an invasive method. The-
re was strong correlation between aortic AIx measured
invasively and brachial artery AIx measured noninva-
sively, by oscillometric method (Arteriograph) (r=0.94;
p<0.001). A comparable level of correlation (r=0.95;
p<0.001) was found between invasively measured and
noninvasively (Artreiograph) calculated central pressure
(SBPao). Significant correlation (r=0.91; p<0.001) was
recorded between invasively measured aortic PWV and
PWV measured noninvasively by use of Arteriograph.
Measurement
Examination should be performed in a quiet room, at
temperature of about 22°C. The patient should avoid tak-
ing food and smoking for 3 hours and alcohol drinks for
10 hours before examination. At least 10-minute rest and
mental relaxation should precede the examination. Mea-
surement is performed in supine position, relaxed, with
legs extended, but not sleeping. The method cannot pro-
vide reliable data in patients with arrhythmia and there-
fore it is not used in these patients. Upper arm cuff is
placed and tightened firmly to produce the state of bra-
chial artery occlusion by suprasystolic pressure value.
Cuff contact with the patient’s chest should be avoided.
Arteriograph measures actual systolic and diastolic pres-
sure first by oscillometric method, then the cuff is de-
flated. This is followed by cuff re-inflation, first to dia-
stolic, then to suprasystolic pressure value (actual systolic
pressure measured +35 mm Hg). Then the device regis-
ters and records signals at systolic and diastolic blood
pressure values for 8–10 seconds. All signals recorded are
processed by computer software designed for this pur-
pose (1.10.0.1). Each of the measurements was perfor-
med twice and the mean value was used in further calcu-
lations.
The study was conducted following the principles of
bioethical standards. The protocol was approved by the
Children’s Hospital Ethics Committee and Central Eth-
ics Committee of Rijeka University School of Medicine. A
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written informed consent was obtained from the parent
or guardian of each child included in the study. Major ad-
olescents signed informed consent by themselves.
Statistical analysis
Descriptive statistics was used to describe the basic
characteristics of age, sex, BMI, anthropometric parame-
ters (waist and hip circumference, jugulum-symphysis
distance), BP and HR. Normality of data distribution
was analyzed using the Kolmogorov-Smirnov test. The
c2-test was used to estimate differences in the distribu-
tion of qualitative variables. Differences in quantitative
variables between study groups were analyzed with the
parametric t-test or nonparametric Mann-Whitney test,
according to their distribution. Calculation of Pearson’s r
correlation coefficient was also performed for certain
quantitative variables.
All statistical tests were performed at the 95% level of
significance; difference between study groups was con-
sidered significant at p<0.05. MedCalc software for Win-
dows version 11.3 (www.medcalc.be) was used for data-
base management and statistical analysis.
Results
There was no significant difference between the pa-
tient group and control group according to age, sex, BMI,
waist and hip circumference, jugulum-symphysis dis-
tance, HR and BP level (differences in variables were an-
alyzed with independent t-test, except for sex, where
c2-test was used) (Table 1).
There was a statistically significant difference in PWVao
between the patient and control group. The subjects hav-
ing received anthracyclines showed a higher PWVao than
controls (p<0.001) (Table 2).
There was no correlation between the cumulative
anthracycline dose and PWVao (r=0.227) in patient group.
PWVao was not increased in patients having received
higher doses of anthracyclines.
There was no significant difference in the mean PWVao
between patients having (n=9) and having not (n=44)
received cyclophosphamide (6.41±2.05 m/s vs. 6.21±1.17
m/s; p=0.790).
There was no sex difference in PWVao value in pa-
tient group (male 6.33±1.35 m/s vs. female 6.08±1.34 m/s;
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TABLE 1













Age (yrs): X±SD 13.59±4.44 12.21±3.03 0.081
BMI (kg/m2): X±SD 20.16±4.63 18.98±3.48 0.162
Hip (cm): X±SD 82.63±17.09 79.87±12.21 0.368
Waist (cm): X±SD 72.18±15.05 67.81±9.94 0.100
Waist to hip ratio: X±SD 0.88±0.07 0.85±0.05 0.034
Jugulum-symphysis (cm): X±SD 47.02±7.45 45.98±5.53 0.441
Systolic BP (mm Hg): X±SD 109.76±16.13 114.44±11.31 0.105
Diastolic BP (mm Hg): X±SD 61.05±8.23 63.01±6.17 0.191
HR (beats/min): X±SD 76.09±14.47 74.49±12.00 0.556
Anthracycline dose (mg/m2) 212±93 0 NA
BMI – body mass index; BP – blood pressure; HR – heart rate
TABLE 2








PWVao (m/s): X±SD 6.24±1.34 5.42±0.69 <0.001
PPao (mm Hg): X±SD 37.81±6.13 35.66±5.41 0.079
SBPao (mm Hg): X±SD 99.10±10.50 97.91±8.71 0.556
MAP (mm Hg): X±SD 78.26±9.07 78.86±6.87 0.728
PWVao – aortic pulse wave velocity; PPao – aortic pulse pressure; SBPao – aortic systolic blood pressure; MAP – mean arterial pressure
p=0.519) and control group (male 5.35±0.79 m/s vs. fe-
male 5.52±0.56 m/s; p=0.415).
In addition, there was no difference between the val-
ues of MAP (p=0.72), PPao (p=0.079), and SBPao (p=
0.556) (Table 2).
Analysis of echocardiography results (Table 3) yielded
no statistically significant difference in left ventricular
parameters of IVSd, LVEDd, LVPWd (p>0.05), LVM (p=
0.656) and LVMI (g/m2.7) (p=0.535).
However, a difference was found in left ventricular FS
(p=0.001), which was lower in patients as compared to
control subjects.
Discussion
Children and adolescents treated with anthracyclines
for a malignant disease had increased aortic stiffness
when compared to the age- and sex-matched healthy
group. In our study, increased aortic stiffness expressed
as an increased PWVao value was found in the group of
children and adolescents treated with anthracyclines at
least a year after completion of chemotherapy.
Long-term survivors of childhood cancer become an
increasing group with a significant risk of premature
heart disease1. The Childhood Cancer Survivor Study,
where 14,358 cancer survivors were compared to their
siblings, has reported a higher risk of heart failure (rela-
tive risk [RR] 5.7), myocardial infarction (RR 4.9), ath-
erosclerosis (RR 10.2), pericardial disease (RR 6.3) and
valvular disease (RR 4.8) in these patients23.
An increase in arterial stiffness causes a premature
return of reflected pulse waves in late systole, increases
central systolic pressure, pulse pressure, and afterload,
causes heart muscle hypertrophy and reduces coronary
perfusion24. Increased stiffness of central arteries has
been demonstrated to have an independent predictive
value for cardiovascular events in adult population8. In
their study including 1207 adolescents, Arnett et al.
found the systolic BP and arterial elasticity to be in-
versely proportional in this population9. Riley et al. re-
port on reduction of arterial elasticity in children with el-
evated BP and cholesterol10. Children of hypertensive
parents have been found to have increased arterial stiff-
ness measured both in the aorta and in the carotid artery,
suggesting the possible genetic component11,12. Only a
few studies report data on normal PWVao values as a
measure of arterial stiffness in children, but these mea-
surements were performed in a small number of children
and with different methods25. Reusz et al. report on a re-
cent study of reference values of carotid-femoral PWV
obtained in more than 1000 children14. Reference values
of PWVao measured by Arteriograph have not yet been
published.
The effect of anthracyclines on arterial stiffness could
be explained with oxidative stress1, structural changes in
the vascular endothelial matrix, or disruption in the reg-
ulation of the arterial wall smooth muscle tone. An-
thracycline increased the effect of inflammatory cyto-
kines, which can cause damage to vascular endothelium26.
If anthracyclines can cause increased arterial stiff-
ness, they could possibly be an additional factor for the
increased number of cardiovascular diseases in long-
-term survivors of childhood cancer.
To the best of our knowledge, there are no published
data on arterial stiffness measurements in children trea-
ted with anthracyclines.
The only study that examined the effect of anthra-
cyclines on arterial stiffness in adults was the one by
Chaosuwannakit et al.15. A significant increase in PWVao
and decrease of aortic distensibility (AoD) from baseline
values occurs 4 months after the administration of an-
thracycline. The measurement of PWV and AoD was per-
formed by phase-contrast cardiovascular magnetic reso-
nance (PC-CMR). In the study by Chaosuwannakit et
al.15, increased arterial stiffness was observed 4 months
after initiation of anthracycline treatment. Presuming
the possibility of reversible condition, it seems reason-
able to measure it a year after chemotherapy completion
or later, to prove the long-term persistence of its effects.
In our study, the measurement of PWVao was performed
in patients that have completed anthracycline therapy a
year or more before.
PWVao values in our study were significantly higher
(p<0.001) in the group of patients previously treated
with anthracyclines than in the control group. The mean
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TABLE 3







IVSd (cm) 0.70±0.18 0.70±0.18 0.913
LVEDd (cm) 4.35±0.66 4.35±0.46 0.978
LVPWd (cm) 0.66±0.18 0.63±0.16 0.394
FS (%) 33.11±4.41 35.88±3.77 0.001
LVM (g) 103.94±64.96 98.47±54.53 0.656
LVMI (g/m2.7) 30.34±10.68 29.12±8.35 0.535
IVSd – diastolic interventricular septal thickness; LVEDd – left ventricular end diastolic diameter; LVPWd – diastolic left ventricular
posterior wall thickness; FS – fractional shortening; LVM – left ventricular mass; LVMI – left ventricular mass index
PWV value was 6.24±1.34 m/s in patient group versus
5.42±0.69 m/s in control group. The values are compara-
ble because the groups did not differ significantly accord-
ing to age, sex, BH, BW, BMI or HR.
There was no difference in systolic, diastolic, mean
BP and PPao value. Since PWVao measurement with
oscillometric method by Arteriograph TensioMed has
been introduced recently, reference or normal values for
children have not yet been published.
In our study, there was no correlation of PWVao with
the dose of anthracycline (r=0.227). Chaosuwannakit et
al.15 found the higher cumulative doses of anthracyclines
to correlate positively with greater reduction of ascend-
ing thoracic AoD, but not with the increase in PWV.
Among other parameters monitored in the present
study, FS was significantly lower in patient group than in
control group, as also reported from other studies27,28.
Other echocardiographic parameters (IVSd, LVEDd,
LVPWd, LVM and LVMI) did not differ significantly be-
tween the groups of patients and healthy subjects.
The limitations of our study were as follows: a hetero-
geneous group of patients regarding anthracycline dose;
inability to compare PWVao values according to anthra-
cycline dosage due to a small number of patients; and the
lack of follow up over time.
Conclusion
The children having completed treatment with an-
thracyclines at least a year ago have higher PWVao values,
implicating the increased arterial stiffness as a known in-
dependent predictor of cardiovascular diseases. It could be
a factor affecting the increased number of cardiovascular
complications in late survivors of childhood cancer.
As we recorded an increased PWVao in patients at
least a year after chemotherapy completion, it appears
that structural and functional changes of arterial wall
caused by anthracyclines can persist for at least one year.
In conclusion, besides their cardiotoxicity, anthracyclines
also increase arterial stiffness, thus additionally contrib-
uting to the increased risk of cardiovascular diseases in
individuals treated for malignant diseases in childhood.
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POVE]ANA KRUTOST ARTERIJA U DJECE LIJE^ENE ANTRACIKLINIMA ZBOG MALIGNE
BOLESTI
S A @ E T A K
Osobe koje su pre`ivjele malignu bolest u djetinjstvu imaju zna~ajno ve}i pobol i smrtnost od kardiovaskularnih
bolesti u odrasloj dobi. Cilj ove studije je bio odrediti mogu li antraciklini primijenjeni u djetinjstvu pove}ati krutost
arterija, koja je dobro poznati nezavisni prediktor kardiovaskularnih bolesti. Pregledano je 53-oje djece i adolescenata
dobi 6–20 godina, u kojih je lije~enje maligne bolesti antraciklinima prema razli~itim protokolima zavr{eno prije naj-
manje godinu dana. Bolesnici su bili bez klini~kih ili laboratorijskih znakova osnovne bolesti ili sr~ane bolesti. Kon-
trolnu skupinu sa~injavalo je 45-ero zdrave djece sli~ne dobi i spola. Krutost arterija je odre|ena mjerenjem brzine
{irenja pulsnog vala (PWV) oscilometrijskom metodom (ure|ajem Arteriograph TensioMed). U ispitanika koji su lije-
~eni antraciklinima PWV je bio zna~ajno ve}i u usporedbi s kontrolnom skupinom (6,24±1,34 m/s prema 5,42±0,69 m/s,
p<0,001). Krutost arterija je bila pove}ana bez obzira na dob, spol, indeks tjelesne mase, sistoli~ki i dijastoli~ki ar-
terijski tlak, srednji arterijski tlak i sr~anu frekvenciju. Mogu}e je da u~inak antraciklina na pove}anje kasne smrtnosti
u osoba lije~enih u djetinjstvu zbog maligne bolesti nije povezan samo s kardiotoksi~nosti, nego i s pove}anom krutosti
arterija.
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